HRP20210606T1 - Spojevi za liječenje stanja svrbeža - Google Patents

Spojevi za liječenje stanja svrbeža Download PDF

Info

Publication number
HRP20210606T1
HRP20210606T1 HRP20210606TT HRP20210606T HRP20210606T1 HR P20210606 T1 HRP20210606 T1 HR P20210606T1 HR P20210606T T HRP20210606T T HR P20210606TT HR P20210606 T HRP20210606 T HR P20210606T HR P20210606 T1 HRP20210606 T1 HR P20210606T1
Authority
HR
Croatia
Prior art keywords
preparation
compound
compound according
solvate
ester
Prior art date
Application number
HRP20210606TT
Other languages
English (en)
Croatian (hr)
Inventor
Amale Hawi
Original Assignee
Trevi Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Trevi Therapeutics, Inc. filed Critical Trevi Therapeutics, Inc.
Publication of HRP20210606T1 publication Critical patent/HRP20210606T1/hr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D489/00Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/06Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with a hetero atom directly attached in position 14
    • C07D489/08Oxygen atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/04Antipruritics

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
HRP20210606TT 2015-04-23 2016-04-22 Spojevi za liječenje stanja svrbeža HRP20210606T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562151618P 2015-04-23 2015-04-23
EP16784019.8A EP3286198B1 (en) 2015-04-23 2016-04-22 Compounds for treating pruritic conditions
PCT/US2016/029024 WO2016172613A1 (en) 2015-04-23 2016-04-22 Compounds for treating pruritic conditions

Publications (1)

Publication Number Publication Date
HRP20210606T1 true HRP20210606T1 (hr) 2021-05-28

Family

ID=57144302

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20210606TT HRP20210606T1 (hr) 2015-04-23 2016-04-22 Spojevi za liječenje stanja svrbeža

Country Status (15)

Country Link
US (1) US9624233B2 (enExample)
EP (1) EP3286198B1 (enExample)
JP (1) JP6744327B2 (enExample)
AU (1) AU2016252892B2 (enExample)
CA (1) CA2981625C (enExample)
CY (1) CY1124163T1 (enExample)
DK (1) DK3286198T3 (enExample)
ES (1) ES2867799T3 (enExample)
HR (1) HRP20210606T1 (enExample)
HU (1) HUE054399T2 (enExample)
LT (1) LT3286198T (enExample)
PL (1) PL3286198T3 (enExample)
PT (1) PT3286198T (enExample)
SI (1) SI3286198T1 (enExample)
WO (1) WO2016172613A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111116597A (zh) * 2018-10-31 2020-05-08 扬子江药业集团江苏紫龙药业有限公司 一种纳布啡游离碱的制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4477456A (en) 1981-07-02 1984-10-16 E. I. Du Pont De Nemours And Company Octahydro-4A,7-ethano- and -etheno-benzofuro[3,2-e]isoquinoline derivatives having analgesic, narcotic antagonist and anorexigenic properties
US7195882B2 (en) * 2003-06-03 2007-03-27 Roche Diagnostics Operations, Inc. Monoclonal antibodies specific for buprenorphine and metabolites thereof
CA2682125C (en) * 2007-03-29 2015-06-16 Progenics Pharmaceuticals, Inc. Peripheral opioid receptor antagonists and uses thereof
EP2935278B1 (en) * 2012-12-19 2017-03-15 Novartis AG Tricyclic compounds for inhibiting the cftr channel

Also Published As

Publication number Publication date
EP3286198A4 (en) 2018-09-26
AU2016252892A1 (en) 2017-10-26
CA2981625A1 (en) 2016-10-27
EP3286198A1 (en) 2018-02-28
CA2981625C (en) 2023-05-23
CY1124163T1 (el) 2022-05-27
PL3286198T3 (pl) 2021-09-06
EP3286198B1 (en) 2021-02-24
HUE054399T2 (hu) 2021-09-28
DK3286198T3 (da) 2021-05-03
SI3286198T1 (sl) 2021-08-31
AU2016252892B2 (en) 2019-05-02
US20160311832A1 (en) 2016-10-27
PT3286198T (pt) 2021-04-26
LT3286198T (lt) 2021-07-12
JP2018513174A (ja) 2018-05-24
US9624233B2 (en) 2017-04-18
JP6744327B2 (ja) 2020-08-19
WO2016172613A1 (en) 2016-10-27
ES2867799T3 (es) 2021-10-20

Similar Documents

Publication Publication Date Title
HRP20200648T1 (hr) Derivati sulfamoilpirolamida i njihova uporaba kao lijekova za liječenje hepatitisa b
HRP20160203T1 (hr) Pripravci koji sadrže 15-hepe i postupci njihove upotrebe
MX372911B (es) Derivados de dolastatina 10 y auristatinas.
BR112015023705A8 (pt) compostos, composições farmacêuticas, usos de um composto, e método para síntese do composto da fórmula (ia)
AR091857A1 (es) INHIBIDORES DE CISTATIONIN-g-LIASA (CSE)
JP2016511753A5 (enExample)
AR091858A1 (es) INHIBIDORES DE CISTATIONIN-g-LIASA (CSE)
ME03757B (me) Prolekovi jaki inhibitornih jedinjenja za lečenje gastorintestinalne inflamatorne bolesti
CU20150014A7 (es) Análogos de piridazina 1,4-disustituida y métodos para el tratamiento de condiciones relacionadas con la deficiencia de smn
HRP20241197T1 (hr) Makrociklični spojevi i primjene istih
IN2014MN01839A (enExample)
HRP20211278T1 (hr) Supstituirani derivati indolina kao inhibitori replikacije denga virusa
HRP20140277T1 (hr) Kompozicija za lijeäśenje cistiäśne fibroze
AR097199A1 (es) Inhibidores de rorc2 y sus métodos de uso
HRP20140605T1 (hr) Nukleozidi uracil-spirooksetana
HRP20210038T1 (hr) Pirolopirimidini za uporabu u infekciji virusom gripe
AR106141A1 (es) Métodos e intermediarios para la preparación de derivados de ácidos biliares
BR112013021566A2 (pt) composto de fórmula, ou um aduto ou sal farmaceuticamente aceitável do mesmo e método de prevenção e/ou tratamento de um indivíduo que compreende a administração ao dito indivíduo uma quantidade terapeuticamente eficaz de um composto de fórmula
HRP20250885T1 (hr) Spojevi kondenziranog tricikličkog piridazinona korisni za liječenje ortomiksovirusnih infekcija
AR088728A1 (es) Moduladores de lxr como prodroga de imidazol
MX2016008665A (es) Derivado basado en 1,2-naftoquinona y metodo de preparacion del mismo.
JP2016518448A5 (enExample)
AR099385A1 (es) Formulaciones de 3-(5-amino-2-metil-4-oxo-4h-quinazolin-3-il)-piperidina-2,6-diona
HRP20230362T1 (hr) Kompozicije koje sadrže triciklične heterorociklične spojeve
HRP20240605T1 (hr) Kristalni oblici eravaciklina